References
Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, Orfeuvre H, Corront B, Feuillard J, Sotto JJ, Bensa JC, Brière F, Plumas J, Jacob MC (2001) Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97:3210–3217. https://doi.org/10.1182/blood.v97.10.3210
Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101:5007–5009. https://doi.org/10.1182/blood-2002-10-3297
Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169:579–586. https://doi.org/10.1111/bjd.12412
Feuillard J, Jacob M-C, Valensi F, Maynadié M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drénou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, le Calvez G, Sainty D, Sotto MF, Trimoreau F, Béné MC (2002) Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99:1556–1563. https://doi.org/10.1182/blood.v99.5.1556
Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F, for GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party) (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98:239–246. https://doi.org/10.3324/haematol.2012.072645
Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M (2019) Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380:1628–1637. https://doi.org/10.1056/NEJMoa1815105
Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA (2017) Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov 7:156–164. https://doi.org/10.1158/2159-8290.CD-16-0999
Grushchak S, Joy C, Gray A, Opel D, Speiser J, Reserva J, Tung R, Smith SE (2017) Novel treatment of blastic plasmacytoid dendritic cell neoplasm. Medicine (Baltimore) 96:e9452. https://doi.org/10.1097/MD.0000000000009452
DiNardo CD, Rausch CR, Benton C et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93:401–407. https://doi.org/10.1002/ajh.25000
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by MS, ITT, DFA, MD, KER, and GM. The first draft of the manuscript was written by MS, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
GM receives research funding from Glycomimetics, Gilead, and Jazz Pharmacuticals, and has served as an advisor/consultant for Abbvie, Agios, BMS, and Genentech. KR has served as a consultant for Pfizer.
Consent to participate
The patient in this case provided verbal consent to receive the treatment described after a discussion of risks and benefits. Consent was recorded in the medical record.
Ethics approval
Because this is a retrospective case report of a single patient and thus not considered human subjects research, the Institutional Review Board of Stanford University waived ethics approval.
Consent for publication
The participant has consented to the submission of the case report to the journal.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Schwede, M., Tan, I.T., Atibalentja, D.F. et al. Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm. Ann Hematol 99, 2973–2975 (2020). https://doi.org/10.1007/s00277-020-04276-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-04276-z